SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Monday, August 12, 2013

SpicyIP Tidbit: Patent Office confirms status of Genentech’s Herceptin patent

Posted on 8:21 PM by Unknown
Following my post yesterday, the Patent Office has finally confirmed the status of the main Herceptin patent 205534 with the following email:

“As per the E-Register, 15th Annuity was due on 03.05.2013 and same has not been paid so far, therefore it shows ceased as of 03.05.2013.However Section 53 of the Patents Act reads with Rule 80 allows the Patentee to pay the same within the extended period not more than six months, if the request for such extension of time is made in Form-4.Therefore, Patentee still can pay the 15th Annuity on or before 03.11.2013 with extension.” 

In other words, the website of the Patent Office was indeed accurate and Genentech had indeed failed to pay the renewal fees. The Patent Office however appears to be ready to accept the renewal fees from Genentech until November 3, 2013 under Rule 80. However I doubt whether companies like Glenmark and Mylan are going to give Genentech a walkover in this regard. 

It is possible to argue that the request for extension in time required, to pay, the renewal fees under Section 53(2) read with Rule 80(1A) can be made only before the expiry of the last date for renewal, which in this case was May 3, 2013. Since the rule uses the word “extension” as opposed to condonation or restoration, it implies that the right should be applied for before the proposed deadline rather than after the deadline, in which case the right has to be “restored” or the delay has to be “condoned”. You can’t “extend” a right which has already been extinguished. In other words Genentech should have applied before the May 3, 2013 deadline for an extension and if granted such an extension by the Patent Office, it could have paid the renewal fees even after May 3, 2013. 

An application under Rule 80 is an affair between the Patent Office and the patentee – Glenmark and Mylan, which want the patent struck off the register will have little opportunity to intervene directly, although they could rake up the issue in a High Court at a later stage. 

Assuming that the Rule 80 route fails, the Patentee still has the option to file an application under Section 60 for “restoration of a lapsed patent”. Such restorations are long drawn affairs since the Patent Office has to advertise the restoration application and any interested party can oppose the restoration of the application. More importantly, the patentee has to be able to give the Patent Office a good enough reason to allow the restoration application – a mere ‘Oops! I forgot’ isn’t going to do the trick.

It is not going to help Genentech’s case that the Government of India is looking for ways to over-ride its patent due to public health concerns. By not paying up on time, Genentech has left the door wide open for the Government of India to exert pressure on the Patent Office to not consider any renewal or extension in the payment of renewal fees. Since the patent was otherwise valid till 2019, this mistake on Genentech’s part is going to cost it, an average of Rs. 150 crores every year (this drug earned Roche/Genentech Rs. 127 crores last year) and with a cancer drug this figure will keep climbing) – which means that over the next six years Genentech could lose approximately Rs. 800-900 crores – this is of course presuming that a biosimilar can enter the market without infringing any other patents owned by Genentech – the renewal fee charged by the patent office for the 15th year is approximately Rs. 12,000.
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in Patent Office | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Ghost Post: Samsung v. Apple Presidential Enforcement Veto
    SpicyIP subscribers recently received a short blurb from Shamnad on this FT article regarding the hypocrisy of stamping 'national inter...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • SpicyIP Tidbit: GI for Pedana Kalamkari Art Form
    Image from here Recently, as The Hindu reports , Pedana Kalamkari art form received GI protection. Members of Vegetable Dye Hand Block Kalam...
  • Loss of an IP Leader: RIP Prof Daruwalla
    Most in the Indian IP firmament may have heard of the doleful demise of one of our IP leaders, Mr. Tehemtan Nasserwanji Daruwalla. He was an...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ▼  August (41)
      • SpicyIP Tidbit: ALCS August Distribution
      • PIP Essay Competition Results Announced: Meet the ...
      • Now Showing: Satyagraha: Bom HC denies an Injuncti...
      • Patenting food: Plumpy’ Nut and more?
      • Bollywood flick Satyagraha faces dispute over its ...
      • Leading IP Academics Fired: Protest Petition Again...
      • Two MHRD IP Chair Professors axed; Reasons unknown
      • FICCI and The George Washington University, Washin...
      • SpicyIP Tidbit: IPA continues communication with P...
      • SpicyIP Tidbit: GI for Pedana Kalamkari Art Form
      • Colgate v Pepsodent: Comparative Advertising
      • SpicyIP Tidbit: Justice KN Basha to be new IPAB ch...
      • IPRS complies with new copyright law & decides to ...
      • Re-imposing curbs on royalty payments to foreigners
      • Debating the CIS Draft Bill on Privacy: Should thi...
      • The BDR compulsory licensing application and the B...
      • Satyajit Ray's sketches and copyright controversies
      • Rihanna's victory in the Topshop T-shirt case
      • When cancer drugs stop being “necessities”: A case...
      • SpicyIP Tidbit: Singers from the South in support ...
      • Loss of an IP Leader: RIP Prof Daruwalla
      • Part II: IPAB revokes Allergan's patent on eye dru...
      • Part I: IPAB revokes Allergan's patent on eye drug...
      • Feedback on draft guidelines for Computer Related ...
      • A naïve report from Parliament on FDI in the Pharm...
      • INTAvening in the Supreme Court: Parallel Imports ...
      • Surprising news! - Roche decides to not ‘pursue’ H...
      • Independent Intellectual Property: Gunning For (or...
      • SpicyIP Tidbit: Special Services announced by WIP...
      • GI News: Kaipad Rice, Nagpur Oranges, Dharmavaram ...
      • SpicyIP Tidbit: Patent Office confirms status of G...
      • The Sholay litigation saga
      • SpicyIP Tidbit: Has Genentech’s main Herceptin pat...
      • Bollywood flick 'I love NY' accused of plagiarisin...
      • The Herceptin patent fiasco at the Indian Patent O...
      • IPO vs IPAB: IT Prowess and Transparency?
      • Ghost Post: Samsung v. Apple Presidential Enforcem...
      • Delhi HC dismisses Rediff.com's Copyright Infringe...
      • UNICEF Supply Annual Report 2012 : India is the La...
      • Raj Anand Moot Court Competition 2013
      • Breaking News: GSK patents challenged: IPAB revoke...
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ►  March (66)
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.